Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. Issue 1 (17th May 2016)

• Record Type: Journal Article
• Authors: Wang, Chen; Jing, Zhi-Cheng; Huang, Yi-Gao; Zhou, Da-Xin; Liu, Zhi-Hong; Meier, Christian; Nikkho, Sylvia; Curram, John; Zhang, Peng; He, Jian-Guo
• Is Part Of: Heart Asia. Volume 8:Issue 1(2016)
• Page Start: 74
• Page End: 82
• Publication Date: 2016-05-17
• DOI: 10.1136/heartasia-2015-010712
• Languages: English
• ISSNs: 2398-5968

Abstract

Abstract : Objective: PATENT-1 and CHEST-1 were pivotal, international phase III trials assessing riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Here we compare Chinese patients from these studies with the overall populations, and report the clinical effect and safety of riociguat in Chinese patients with PAH and CTEPH. Methods: PATENT-1 was a 12-week, randomised, double-blind, placebo-controlled trial of riociguat (maximum 2.5 mg three times daily or 1.5 mg three times daily (exploratory) in patients with PAH. CHEST-1 was a 16-week, randomised, double-blind, placebo-controlled trial of riociguat (maximum 2.5 mg three times daily) in patients with inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy. The primary endpoint in each study was change from baseline to study end in 6 min walking distance (6MWD). Secondary endpoints included pulmonary vascular resistance (PVR), N-terminal prohormone of brain natriuretic peptide, WHO functional class (FC), and time to clinical worsening. Results: Chinese patients in PATENT-1 (n=77) and CHEST-1 (n=32) were younger and had better baseline 6MWD and WHO FC versus the overall population. Riociguat increased 6MWD versus placebo in Chinese patients in PATENT-1 and CHEST-1, with a greater increase observed in CHEST-1 (least-squares mean differences +46 m and +102 m in PATENT-1 and CHEST-1, respectively). Riociguat also improved several secondary endpoints in both studies, and was well tolerated. Conclusions: Chinese patients displayed differences in baseline characteristics versus the overall populations in PATENT-1 and CHEST-1. Riociguat improved 6MWD, PVR, WHO FC, and other clinical outcomes in Chinese patients with PAH or CTEPH. Trial registration number: PATENT-1: NCT00810693, Results; CHEST-1 NCT00855465, Results.